Study of Hepcidin Activity in Acute Leukemic Patients

Abstract

Acute leukemia is the term used to describe the development of immature bone marrow-derived cells (blasts), which may have an impact on the peripheral circulation or solid organs. This study aimed to evaluate the hepcidin activity in erythropoiesis in patients with acute leukemia (ALL, AML). This study was conducted between November 2021 to May 2022 at the Imam Hussein Center for Oncology and Hematology (Al-Husseini Hospital) in Karbala and Baghdad Teaching Hospital in the Medical City in Baghdad. (65) samples were collected from patients with acute lymphocytic leukemia, both lymphatic and myeloid types, and (36) of the samples as a control group. Our results show that the statistical analysis of hepcidin is high significant difference (P≤ 0.05) in acute leukemia patients compared to healthy people. As well as a significant difference (P≤ 0.05) in iron and ferritin levels in acute leukemia patients compared to the control group.